Uncategorized
Iluvien finds niche for treating DME
Backed by solid clinical trial data, Iluvien has become an invaluable third-level treatment option for chronic diabetic macular edema, according to one clinician.Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) is a non-bioerodible device designed to release fluocinolone acetonide at a rate of 0.25 µm per day for 36 months.